GlassScriptPhysician profile
Jeffrey S Cook
NPI 1700378403
$2,765.74
in general payments reported to CMS, 2019-2025
19 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $305 · 2023: $498 · 2024: $608 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $450.36 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $309.27 | 2021-2024 | Camzyos |
| Esperion Therapeutics, INC. | $292.58 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $261.58 | 2021-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.02 | 2021-2025 | Jardiance |
| Philips North America LLC | $234.65 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Pfizer INC. | $170.57 | 2021-2025 | |
| Amarin Pharma, INC. | $164.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $151.14 | 2021-2025 | |
| Lilly USA, LLC | $114.87 | 2025 | |
| Merck Sharp & Dohme LLC | $98.80 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $67.87 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.82 | 2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $35.83 | 2025 | |
| Scpharmaceuticals INC. | $28.62 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $26.96 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $25.88 | 2023 | Inpefa |
| Boston Scientific Corporation | $21.64 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.